Axonics sacral neuromodulation system for treating refractory overactive bladder: a NICE medical technologies guidance

Poole, Ruth Louise, Dale, Megan, Morgan, Helen, Oladapo, Tosin, Brookfield, Rebecca and Morris, Rhys 2022. Axonics sacral neuromodulation system for treating refractory overactive bladder: a NICE medical technologies guidance. Applied Health Economics and Health Policy 20 (3) , 305–313. 10.1007/s40258-021-00701-0

PDF Available under License Creative Commons Attribution Non-commercial. Download (651kB)

Abstract

The Axonics sacral neuromodulation (SNM) system can be used by people with refractory overactive bladder (OAB) to reduce symptoms of urge urinary incontinence and urinary frequency, where conservative treatments have failed or are not suitable. It is the first system for this indication that makes use of a rechargeable battery to prolong the lifespan of the implanted device, with the potential advantage of reducing the frequency of surgical replacement procedures and associated complications. We describe the evidence considered by the UK National Institute of Health and Care Excellence (NICE) in their evaluation of this evidence, supported by Cedar Healthcare Technology Research Centre. Two observational studies provided descriptive data that suggested improvement in control of symptoms after implantation of the Axonics SNM system; however, there was no peer-reviewed evidence that directly compared rechargeable and non-rechargeable SNM systems. In the absence of long-term data, economic modelling relies on the accuracy of battery life estimates. The evidence supports the case for adopting the Axonics SNM system for treating refractory OAB, when conservative treatment or treatment with medicines has not worked. This conclusion is consistent with other relevant NICE guidelines. Use of Axonics SNM technology in the UK National Health Service (NHS) is associated with a potential cost saving of £6025 per person over a 15-year period when compared with an equivalent non-rechargeable SNM system, assuming the claimed battery life estimate (a minimum of 15 years) is accurate. The cost savings are estimated to start around 6 years after implantation.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Academic & Student Support Service Engineering Medicine
Additional Information:	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Publisher:	Springer
ISSN:	1175-5652
Date of Acceptance:	8 November 2021
Last Modified:	05 Jan 2024 03:18
URI:	https://orca.cardiff.ac.uk/id/eprint/149808

Actions (repository staff only)

Edit Item